Showing results (101-110 of 366) with videos related to

Sort By:
Pageof 37
Lung Cancer (Amsterdam, Netherlands)|January 11, 2015
Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensusFederico Cappuzzo, Denis Moro-Sibilot, Oliver Gautschi, et al.
Experimental Hematology & Oncology|November 22, 2014
Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trialTeresa Moran, Enriqueta Felip, Vicki Keedy, et al.
JTO Clinical and Research Reports|August 11, 2025
Phase 3 Trials of Neoadjuvant, Perioperative, and Adjuvant Chemoimmunotherapy for Resectable, Early-Stage NSCLC: Comprehensive Review and Detailed AnalysisJay M Lee, Alessandro Brunelli, Amy L Cummings, et al.
Frontiers in Medicine|June 16, 2022
Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying CancerPatricia Iranzo, Ana Callejo, Juan David Assaf, et al.
Clinical Lung Cancer|February 4, 2018
Second-Line Treatment Options in Non-Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic OncologyCesare Gridelli, Paul Baas, Fabrice Barlesi, et al.
Clinical Pharmacology in Drug Development|March 31, 2021
Results of a Dose-Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerEnriqueta Felip, Mauricio Burotto, Zanete Zvirbule, et al.
The Journal of Thoracic and Cardiovascular Surgery|September 21, 2025
TROPION-Lung12: A phase 3 study of adjuvant datopotamab deruxtecan and rilvegostomig in ctDNA-positive or high-risk pathology stage I non-small cell lung cancerDavid R Jones, Isabelle Opitz, David Harpole, et al.
Scientific Reports|November 2, 2021
Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohortSusana Cedres, Juan-David Assaf, Patricia Iranzo, et al.
Cancer Research Communications|July 14, 2026
Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non-Small Cell Lung Cancer: Insights From the EVOKE-01 StudyEnriqueta Felip, Peiwen Kuo, Pilar Garrido, et al.
Future Oncology (London, England)|May 22, 2023
HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLCHelena A Yu, James Chih-Hsin Yang, Hidetoshi Hayashi, et al.
Pageof 37